K2M Group Holdings, Inc. (NASDAQ:KTWO) – William Blair issued their Q3 2017 EPS estimates for K2M Group Holdings in a research report issued on Monday. William Blair analyst K. Krum anticipates that the medical device company will post earnings of ($0.18) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for K2M Group Holdings’ Q4 2017 earnings at ($0.15) EPS, FY2017 earnings at ($0.80) EPS, Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.14) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at $0.01 EPS and FY2018 earnings at ($0.43) EPS.
K2M Group Holdings (NASDAQ:KTWO) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The company had revenue of $65.70 million for the quarter, compared to the consensus estimate of $66.26 million. K2M Group Holdings had a negative return on equity of 15.45% and a negative net margin of 16.21%. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.27) EPS.
ILLEGAL ACTIVITY WARNING: This story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2017/10/13/k2m-group-holdings-inc-to-post-q3-2017-earnings-of-0-18-per-share-william-blair-forecasts-ktwo.html.
A number of other equities analysts have also recently commented on the company. Cowen and Company reissued a “buy” rating and set a $26.00 target price on shares of K2M Group Holdings in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of K2M Group Holdings in a report on Thursday, June 22nd. JMP Securities reissued an “outperform” rating and set a $30.00 target price (up previously from $27.00) on shares of K2M Group Holdings in a report on Wednesday, June 28th. Royal Bank Of Canada reissued a “buy” rating and set a $26.00 target price on shares of K2M Group Holdings in a report on Friday, September 22nd. Finally, Needham & Company LLC reissued a “strong-buy” rating and set a $27.00 target price (down previously from $29.00) on shares of K2M Group Holdings in a report on Monday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $25.60.
In related news, insider John Philip Md Kostuik sold 1,090 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $24.08, for a total value of $26,247.20. Following the completion of the sale, the insider now owns 201,961 shares of the company’s stock, valued at $4,863,220.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Gregory S. Cole sold 39,357 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $23.37, for a total value of $919,773.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,129 shares of company stock valued at $1,033,644. Insiders own 5.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of KTWO. TimesSquare Capital Management LLC increased its stake in K2M Group Holdings by 31.5% during the second quarter. TimesSquare Capital Management LLC now owns 2,888,020 shares of the medical device company’s stock worth $70,352,000 after acquiring an additional 691,000 shares during the last quarter. Citadel Advisors LLC increased its stake in K2M Group Holdings by 3,357.5% during the first quarter. Citadel Advisors LLC now owns 628,808 shares of the medical device company’s stock worth $12,897,000 after acquiring an additional 610,621 shares during the last quarter. Point72 Asset Management L.P. increased its stake in K2M Group Holdings by 114.0% during the first quarter. Point72 Asset Management L.P. now owns 555,500 shares of the medical device company’s stock worth $11,393,000 after acquiring an additional 295,900 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its stake in K2M Group Holdings by 110.8% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 530,000 shares of the medical device company’s stock worth $10,870,000 after acquiring an additional 278,562 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in K2M Group Holdings during the second quarter worth $6,595,000. 97.86% of the stock is owned by institutional investors.
About K2M Group Holdings
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.